Evidence map›Paper›PMID 41807605›Full record

ArticleBone marrow transplantation2026

Tuberculosis after allogeneic hematopoietic stem cell transplantation: a decade nationwide case-control retrospective study in low-incidence country.

G Imbert de Trémiolles, S Nguyen, D Lebeaux, N de Castro, N Veziris, E Brissot, B Lefevre, S Ducastelle Leprêtre, B Lioure, R Redjoul and 11 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

G Imbert de TrémiollesService de maladies infectieuses et tropicales, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France.
S NguyenService d'hématologie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital de la Pitié-Salpêtrière, Paris, France.
D LebeauxDépartement de maladies infectieuses et tropicales, Université Paris Cité, Assistance publique des hôpitaux de Paris (AP-HP), Hôpital Saint-Louis Lariboisière, Paris, France.
N de CastroDépartement de maladies infectieuses et tropicales, Université Paris Cité, Assistance publique des hôpitaux de Paris (AP-HP), Hôpital Saint-Louis Lariboisière, Paris, France.
N VezirisCentre d'Immunologie et des Maladies Infectieuses, Paris, France, APHP, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Sorbonne Université, Paris, France.
E BrissotService d'hématologie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint Antoine, Paris, France.ORCID 0000-0003-4471-418X
B LefevreService des Maladies Infectieuses et Tropicales, Université de Lorraine, CHRU-Nancy, Nancy, France.
S Ducastelle LeprêtreCentre Hospitalier Lyon Sud, Service d'hématologie, Université Claude Bernard - Lyon 1, Hospices Civils de Lyon (HCL), Pierre-Bénite, France.
B LioureService d'hématologie, Université de Strasbourg, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
R RedjoulService d'hématologie, Université Paris Est Créteil, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Henri Mondor, Paris, Créteil, France.
C Castilla LlorenteDépartement d'hématologie, Gustave Roussy Cancer Campus Grand Paris, Villejuif, Cedex, France.
F MesnilAgence de la biomédecine, direction Prélèvement et Greffe de CSH, pôle Evaluation Biostatistique, Saint Denis La Plaine, Cedex, France.
C FaucherAgence de la biomédecine, direction Prélèvement et Greffe de CSH, pôle Evaluation Biostatistique, Saint Denis La Plaine, Cedex, France.
F SuarezService d'hématologie, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France.
F AderCentre International de Recherche en Infectiologie (CIRI), Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, Lyon, France.
A ConradCentre International de Recherche en Infectiologie (CIRI), Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, Lyon, France.
L Van den BogaartService des maladies infectieuses et tropicales, Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Lyon, France.
B RanqueService de médecine interne, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Paris, France.
F LanternierService de maladies infectieuses et tropicales, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France.
O LortholaryService de maladies infectieuses et tropicales, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France.
E LafontService de maladies infectieuses et tropicales, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France. emmanuel.lafont@aphp.fr.ORCID 0000-0001-9931-4285

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data regarding tuberculosis (TB) in allogeneic hematopoietic stem cell transplant (Allo-HSCT) recipients in low areas of incidence is scarce. The objectives were to describe incidence, risk factors, clinical manifestations, treatment and outcome of tuberculosis after Allo-HSCT. We conducted a nationwide multicenter retrospective cohort study of adult Allo-HSCT recipients diagnosed with TB between 2012 and 2023 in France. Patients were identified through the SociétéFrancophone de Greffe de Moelle et de Thérapie cellulaire database. Each case was matched with 3 controls. Thirty-five patients were identified. The incidence rate was 60 per 100,000 patient-years. In multivariate analysis, being born in a high-incidence country for TB (OR = 19.4 [4.49-135.79], p < 0.001) was independently associated with TB. The median time from Allo-HSCT to TB diagnosis was 147 [range 30-7244] days. Extrapulmonary involvement was observed in 82% of cases (28/34). Median duration of anti-tuberculous therapy was 273 [range 10-424] days. Eight patients (25%) presented severe adverse reactions to anti-TB drugs. At the end of follow-up, two TB relapsed (6%). TB attributable mortality was 9% (N = 3, among a total of 7 deaths). Overall, our findings showed that TB post Allo-HSCT was rare and severe in low-incidence countries for TB, such as France. LTBI screening should be implemented for transplant candidates born in high-incidence countries for TB.

Indexed as

Hematopoietic Stem Cell TransplantationTuberculosisAdolescentAdultCase-Control StudiesFemaleFranceHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsTransplantation, HomologousYoung Adult

Identifiers

PMID41807605

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.